RecruitingNot ApplicableNCT06202846

Identification of Y Chromosome From Free Circulating DNA in Patients With Turner Syndrome

Sponsor

University Hospital, Strasbourg, France

Enrollment

50 participants

Start Date

Feb 28, 2024

Study Type

INTERVENTIONAL

Conditions

Turner Syndrome

Summary

Turner syndrome affects 1/2500 female newborns. It is characterized by a short stature, gonadal dysgenesis and bone anomalies. It is secondary to X chromosome abnormality. The clinical course can be marked by various complications, including degeneration of gonadal streaks into cancer (gonadoblastoma). The risk of gonadoblastoma is increased by the presence of Y chromosome, with a risk of 19 to 43%. However, Y chromosome material may be difficult to identify due to its mosaic state, at varying rates depending on the tissue. Free circulating DNA (cfDNA) corresponds to fragments of extracellular DNA present in the plasma, released into the circulation during cell death processes by the various tissues of the body. Due to its multiple tissue origins and easy collection, cfDNA appears to be a suitable matrix for searching for low mosaic Y chromosome sequences in patients with Turner syndrome. The main objective of the study is to develop a cfDNA-based test to look for Y chromosome sequences in 50 patients with Turner syndrome. The secondary objectives are to determine the mosaic detection threshold of this test and to compare the performance of this test with the fluorescence in situ hybridization (FISH) technique used in routine diagnosis. This study will assess the detection sensitivity of this test and its relevance in a clinical context.

Eligibility

Sex: FEMALEMin Age: 2 YearsMax Age: 74 Years

Inclusion Criteria4

patient aged 2 to 74 years
with a diagnosis of Turner syndrome confirmed by karyotype
who have given their consent or whose legal representative(s) have given their consent(s) consent(s) to participate in the study
affiliated to the French Social Security system or benefiting from such a system

Exclusion Criteria3

male phenotype
patient or legal representative(s) with comprehension difficulties (linguistic, etc.)
patients covered by articles L.1121-5 to L.1121-8 of the CSP (French Public Health Code)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICcfDNA analysis

In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH. compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH.